Funder
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences
Deutsche Forschungsgemeinschaft
Michelson Prize and Grants
Parker Institute for Cancer Immunotherapy
National Science Foundation
Publisher
Springer Science and Business Media LLC
Subject
Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology
Reference51 articles.
1. Frangoul, H. et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. New Engl. J. Med. 384, 252–260 (2021).
2. Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science https://doi.org/10.1126/science.aba7365 (2020).
3. US National Laboratory of Medicine. A safety and efficacy study evaluating ctx110 in subjects with relapsed or refractory B-cell malignancies (CARBON). ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT04035434 (2019).
4. US National Laboratory of Medicine. CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy for relapsed/refractory B cell non-Hodgkin lymphoma. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT04637763 (2020).
5. US National Laboratory of Medicine. Transplantation of clustered regularly interspaced short palindromic repeats modified hematopoietic progenitor stem cells (CRISPR_SCD001) in patients with severe sickle cell disease. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT04774536 (2021).
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献